What's Going On With Moleculin Biotech Shares Wednesday?
What's Going On With Moleculin Biotech Shares Wednesday?
The data comes from the company's abstract titled, "Annamycin, a non-cardiotoxic anthracycline, demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML," presented at the American Society of Hematology (ASH) Annual Meeting held Dec. 7-10, in San Diego, CA.Moleculin Biotech, Inc. (NASDAQ:MBRX) shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model.
Moleculin Biotech, Inc. (納斯達克:MBRX) 的股票在週三上漲，因爲該公司宣佈在線發佈其 Annamycin 抗 Venetoclax 急性髓系白血病模型的前臨床數據。
What To Know: The preclinical data suggests that Annamycin effectively targets acute myeloid leukemia (AML) cell lines resistant to Cytarabine (Ara-C) and Venetoclax (VEN) in lab tests using cells from patients with advanced or relapsed AML.
要點：前臨床數據顯示，Annamycin 在使用來自晚期或複發性急性髓系白血病患者的細胞的實驗室測試中，有效靶向對 Cytarabine (Ara-C) 和 Venetoclax (VEN) 有抵抗力的急性髓系白血病 (AML) 細胞系。
"The preliminary clinical activity of Annamycin in heavily pretreated, relapsed/refractory AML patients who had progressive disease following Ara-C and VEN is very exciting and would provide a much needed treatment option for other patients who otherwise have very poor outcomes, said Giovanni Martinelli, Lead of the EU-funded IMPACT-AML program and Moleculin Scientific Advisory Board member.
「Annamycin 在經過重度預處理且對 Ara-C 和 VEN 進展性疾病有反應的復發/難治性急性髓系白血病患者中初步的臨床活性非常令人興奮，這將爲其他預後較差的患者提供一個急需的治療選擇，」歐洲資助的 IMPACt-AML 項目首席負責人、Moleculin 科學顧問委員會成員 Giovanni Martinelli 說。
The data comes from the company's abstract titled, "Annamycin, a non-cardiotoxic anthracycline, demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML," presented at the American Society of Hematology (ASH) Annual Meeting held Dec. 7-10, in San Diego, CA.
該數據來自公司題爲「Annamycin，一種非心臟毒性的蒽環類藥物，展示獨特的器官趨向性及其對 Ara-C 和 Venetoclax 抗性急性髓系白血病的活性」的摘要，該摘要在於加利福尼亞州聖地亞哥於12月7日至10日舉行的美國血液學會（ASH）年會上發佈。
The company is advancing Annamycin development with the Phase 3 MIRACLE trial (MB-108), evaluating Annamycin in combination with Cytarabine for the treatment of relapsed or refractory AML. This global trial, including sites in the United States, is set to begin patient treatment during the 2025 first quarter.
該公司正在推進 Annamycin 的開發，進行 3 期 MIRACLE 試驗（Mb-108），評估 Annamycin 與 Cytarabine 聯合用於治療復發或難治性急性髓系白血病。這項全球試驗，包括在美國的研究地點，計劃於2025年第一季度開始患者治療。
Related Link: Integral Ad Science Chief Financial Officer Trades $80K In Company Stock
相關鏈接：Integral Ad Science 首席財務官交易了 $8萬 的公司股票
MBRX Price Action: At the time of publication, Moleculin shares are trading 12% higher at $2.59, according to data from Benzinga Pro.
MBRX 價格動態：根據 Benzinga Pro 的數據，截至發佈時，Moleculin 的股票上漲了 12%，交易價格爲 $2.59。
Image: Emilian Danaila from Pixabay
圖片: Emilian Danaila 來自 Pixabay
譯文內容由第三人軟體翻譯。